Intuitive Surgical, Inc. vs Liquidia Corporation Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $423.15 (market cap $149.10B), while Liquidia Corporation Common Stock trades at $34.26 (market cap $2.40B). The key difference: Intuitive Surgical, Inc. is far larger — about 62.1× Liquidia Corporation Common Stock's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Liquidia Corporation Common Stock for 0 Days on average.
| ISRG | LQDA | |
|---|---|---|
Market Cap | $149.10B | $2.40B |
Volume | 1,732,647 | 2,857,547 |
Sector | Health | Health |
52-Week High | $592.85 | $91.03 |
52-Week Low | $332.02 | $22.02 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.89B | $2.30B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $420.24, down 1.73% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The company reported $10.06B in 2025 revenue with 28.45% net margins, while technical indicators show a bullish trend with support at $414. Recent news highlights international expansion in India and Japan to offset China weakness.
ISRG presents a compelling investment case with 70% analyst buy ratings and a $480.78 price target offering 14% upside. Key risks include competitive pressures in robotic surgery and procedure growth concerns, but the company's market leadership and recurring revenue model support long-term growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →